Legend seeks $250M after positive #ASCO22 data, but challenges remain for the J&J partner
J&J-partnered Legend Biotech has had its share of both good and bad news in recent weeks, and execs evidently believe the former outweighs the latter.
The company announced Monday afternoon that it’s putting together a new public offering, with the goal of raising $250 million. Monday’s move comes after Carvykti, the approved CAR-T therapy sold by Legend and J&J, reported positive durability data at #ASCO22, but also after Legend scrapped a follow-up CAR-T trial earlier this month.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.